Bupropion Dosing for Smoking Cessation
For smoking cessation, start bupropion at 150 mg once daily for 3 days, then increase to 150 mg twice daily (maximum 300 mg/day) for 7-12 weeks, with the quit date set 1-2 weeks after starting the medication 1, 2.
Standard Dosing Regimen
The evidence-based dosing schedule is straightforward:
- Days 1-3: 150 mg orally once daily
- Day 4 through 7-12 weeks: 150 mg orally twice daily (if tolerated)
- Maximum daily dose: 300 mg per day
- Quit date timing: Set for 1-2 weeks after initiating medication
This regimen is consistently recommended across multiple high-quality guidelines 1, 2 and represents the standard approach validated in clinical trials.
Treatment Duration and Extension
Standard treatment duration is 7-12 weeks 1, 2. However, therapy may be extended to promote continued cessation (6 months to 1 year) while attempting to avoid longer periods if possible 1. The British Association for Psychopharmacology guidelines specifically note 7-12 weeks as the evidence-based duration 2.
Combination Therapy Considerations
Bupropion can be combined with nicotine replacement therapy (NRT) for enhanced efficacy 1. When using combination therapy, follow the same bupropion dosing schedule. The NCCN guidelines list "Bupropion ± NRT" as a standard option, indicating this combination is safe and potentially more effective than either agent alone 1.
Critical Safety Contraindications
Bupropion is absolutely contraindicated in patients with:
- Seizure disorders or conditions that increase seizure risk (stroke, brain metastases, head trauma)
- Current use of MAO inhibitors (increased risk of hypertensive reactions)
- Concurrent tamoxifen use
- Closed-angle glaucoma 1
The seizure risk is approximately 0.1% at the recommended 300 mg/day dose 2, but this risk increases substantially with higher doses or in patients with predisposing factors.
Monitoring and Side Effects
Common side effects include insomnia and dry mouth 1, 2. These are generally mild and transient. Importantly, recent large-scale evidence from the EAGLES trial (n=8,058 participants) found that neuropsychiatric adverse events with bupropion were not significantly increased compared to nicotine patches or placebo, even in patients with psychiatric disorders 1.
Monitor for:
- Development or worsening of depression, suicidal ideation, or behavioral changes (though evidence shows this risk is not elevated above placebo)
- Blood pressure changes (though no significant changes in mean BP have been reported in trials)
- Seizure activity
Comparative Efficacy Context
While bupropion is effective for smoking cessation, the most recent guidelines indicate it is less effective than varenicline or combination NRT 2. A 2023 Cochrane review found bupropion increases quit rates compared to placebo (RR 1.64) but is likely less effective than varenicline (RR 0.73 favoring varenicline) or combination NRT 2. However, bupropion remains a valuable option, particularly for patients who:
- Cannot tolerate or have contraindications to varenicline
- Have comorbid depression (bupropion has antidepressant properties)
- Need assistance with smoking cessation and weight management (bupropion attenuates post-cessation weight gain) 3
Dose Adjustments
If the patient cannot tolerate 300 mg/day, they may remain on 150 mg once daily 1. Dose adjustments may be considered as clinically indicated. In patients with moderate to severe hepatic impairment, reduce the total daily dose accordingly (specific guidance should follow manufacturer recommendations).
Common Pitfall to Avoid
Do not start both doses simultaneously—the 3-day titration period at 150 mg once daily is essential to minimize side effects and assess tolerability before advancing to the full therapeutic dose of 300 mg/day.